



NOV 22 2006

Equivalent of Form PTO/SB/08A (07-06)

Approved for use through 09/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

1 of 12


Complete if Known

Application Number	10/701,844
Filing Date	November 4, 2003
First Named Inventor	W. James JACKSON
Art Unit	1645
Examiner Name	Baskar, Padmavathi
Attorney Docket Number	2479.0040002/EJH/C-K

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS


586053v1

Examiner Signature		Date Considered	8/1/01
--------------------	---	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Substitute for form 1449B/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/701,844
Sheet	1	of	4	Filing Date	November 4, 2003
				First Named Inventor	W. James JACKSON
				Art Unit	1645
				Examiner Name	Baskar, Padmavathi
				Attorney Docket Number	2479.0040002/EJK/C-K

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			
	NPL1	Amersdorfer, P., et al., "Molecular Characterization of Murine Humoral Immune Response to Botulinum Neurotoxin Type A Binding Domain as Assessed by Using Phage Antibody Libraries," <i>Infect. Immun.</i> 65:3743-3752, American Society For Microbiology (1997)			T ²
	NPL2	Barenkamp, S.J. and St. Geme III, J.W., "Identification of Surface-Exposed B-Cell Epitopes on High-Molecular-Weight Adhesion Proteins of Nontypeable <i>Haemophilus influenzae</i> ," <i>Infect. Immun.</i> 64:3032-3037, American Society For Microbiology (1996)			
	NPL3	Batteiger, B.E., et al., "Species-, Serogroup-, and Serovar-Specific Epitopes Are Juxtaposed in Variable Sequence Region 4 of the Major Outer Membrane Proteins of Some <i>Chlamydia trachomatis</i> Serovars," <i>Infect. Immun.</i> 64:2839-2841, American Society For Microbiology (1996)			
	NPL4	Baughn, R.E., et al., "Epitope Mapping of B-Cell Determinants on the 15-Kilodalton Lipoprotein of <i>Treponema pallidum</i> (Tpp15) with Synthetic Peptides," <i>Infect. Immun.</i> 64:2457-2466, American Society For Microbiology (1996)			
	NPL5	Brown, D.R., et al., "Identification and Characterization of a Neutralizing Monoclonal Antibody Against Botulinum Neurotoxin, Serotype F, Following Vaccination With Active Toxin," <i>Hybridoma</i> 16:447-456, Mary Ann Leibert, Inc. (1997)			
	NPL6	Burnie, J.P., et al., "Defining Antibody Targets in <i>Streptococcus oralis</i> Infection," <i>Infect. Immun.</i> 64:1600-1608, American Society For Microbiology (1996)			
	NPL7	Christiansen, G., et al., "Molecular biology of the Chlamydia pneumoniae surface," <i>Scand. J. Infect. Dis. Suppl.</i> 104:5-10, Blackwell Science, Ltd. (1997)			
	NPL8	Cunningham, M.W., et al., "Molecular Analysis of Human Cardiac Myosin-Cross-Reactive B- and T-Cell Epitopes of the Group A Streptococcal M5 Protein," <i>Infect. Immun.</i> 65:3913-3923, American Society For Microbiology (1997)			
	NPL9	Davies, D.R. and Cohen, G.H., "Interactions of protein antigens with antibodies," <i>Proc. Natl. Acad. Sci. USA</i> 93:7-12, National Academy of Sciences (1996)			
	NPL10	De Sa, C., "La protéine majeure de la membrane externe de <i>Chlamydia</i> : structure et fonctions," <i>Vet. Res.</i> 27: 317-331, ZDP Sciences (1996)			

Examiner Signature	<i>Rebecca Barker</i>	Date Considered	<i>11/07</i>
--------------------	-----------------------	-----------------	--------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Substitute for form 149B/PTO-842 INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
Sheet	2	of	4	Application Number	10/701,844
				Filing Date	November 4, 2003
				First Named Inventor	W. James JACKSON
				Art Unit	1645
				Examiner Name	Baskar, Padmavathi
				Attorney Docket Number	2479.0040002/EJK/C-K

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
✓P	NPL11	Delvig, A.A., et al., "Immune responses to linear epitopes on the PorB protein of <i>Neisseria meningitidis</i> in patients with systemic meningococcal disease," <i>Microbiol.</i> 142:2491-2498, Society for General Microbiology (1996)	
	NPL12	Deslauriers, M., et al., "Identification of Murine Protective Epitopes on the <i>Porphyromonas gingivalis</i> Fimbrillin Molecule," <i>Infect. Immun.</i> 64:434-440, American Society for Microbiology (1996)	
	NPL13	Duij, B., et al., "Fine Mapping of Outer Membrane Protein P2 Antigenic Sites Which Vary During Persistent Infection by <i>Haemophilus influenzae</i> ," <i>Infect. Immun.</i> 64:4673-4679, American Society For Microbiology (1996)	
	NPL14	Fan, J. and Stephens, R.S., "Antigen Conformation Dependence of <i>Chlamydia trachomatis</i> Infectivity Neutralization," <i>J. Infect. Dis.</i> 176:713-721, University of Chicago Press (1997)	
	NPL15	Ghadjari, A., et al., "Epitope mapping <i>Candida albicans</i> proteinase (SAP 2)," <i>FEMS Immunol. Med. Microbiol.</i> 19:115-123, Elsevier Science (1997)	
	NPL16	Janeway, C., et al., <i>Immunogenicity</i> , John Wiley & Sons, Inc., New York, NY, pp. 65-71 (1989)	
	NPL17	Ji, Y., et al., "Intranasal immunization with CSa peptidase prevents nasopharyngeal colonization of mice by the group A Streptococcus," <i>Infect. Immun.</i> 65: 2080-2087, American Society for Microbiology (1997)	
	NPL18	Lainson, F.A., et al., "Characterization of epitopes involved in the neutralization of <i>Pasteurella haemolytica</i> serotype A1 leukotoxin," <i>Microbiol.</i> 142:2499-2507, Society for General Microbiology (1996)	
	NPL19	Li, C.H., et al., "β-Endorphin Omission Analogs: Dissociation of Immunoreactivity from Other Biological Activities," <i>Proc. Natl. Acad. Sci. USA</i> 77:3211-3214, National Academy of Sciences (1980)	
✓A	NPL20	Méchin, M., et al., "Identification of Surface-Exposed Linear B-Cell Epitopes of the Nonfimbrial Adhesin CS31A of <i>Escherichia coli</i> by Using Overlapping Peptides and Antipeptide Antibodies," <i>Infect. Immun.</i> 64:3555-3564, American Society for Microbiology (1996)	

Examiner Signature	<i>John Berlin</i>	Date Considered	8/1/07
--------------------	--------------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

3 of 4

Complete if Known

Application Number	10/701,844
Filing Date	November 4, 2003
First Named Inventor	W. James JACKSON
Art Unit	1645
Examiner Name	Baskar, Padmavathi
Attorney Docket Number	2479.0040002/EJK/C-K

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL21	Morris, G.E., <i>Methods in Molecular Biology</i> , Vol. 66:Epitope Mapping, Morris, G.E., ed., Humana Press, Totowa, NJ (1996)	
	NPL22	Oettinger, T., et al., "Characterization of the Delayed Type Hypersensitivity-Inducing Epitope of MPT64 from <i>Mycobacterium tuberculosis</i> ," <i>Scand. J. Immunol.</i> 45:499-503, Blackwell Science, Ltd. (1997)	
	NPL23	Pal, S., et al., "Monoclonal immunoglobulin A antibody to the major outer membrane protein of <i>Chlamydia trachomatis</i> mouse pneumonitis biovar protects mice against a genital chlamydial challenge," <i>Vaccine</i> 15:575-582, Elsevier Science (1997)	
	NPL24	Pal, S., et al., "Immunization with an Acellular Vaccine Consisting of the Outer Membrane Complex of <i>Chlamydia trachomatis</i> Induces Protection against a Genital Challenge," <i>Infect. Immun.</i> 65:3361-3369, American Society for Microbiology (1997)	
	NPL25	Read, T.D., et al., "Genome sequence of <i>Chlamydophila caviae</i> (<i>Chlamydia psittaci</i> GPIC): examining the role of niche-specific genes in the evolution of the Chlamydiaceae," <i>Nucleic Acids Res.</i> 31:2134-2147, Oxford University Press (2003)	
	NPL26	Roitte, I., et al., <i>Immunology</i> , Roitt, I., Brostoff, J., and Male, D., eds., St. Louis, MO, CV. Mosby, pp. 7.1-7.10 (1989)	
	NPL27	Saint-Remy, J.R., "Epitope mapping: a new method for biological evaluation and immunotoxicology," <i>Toxicology</i> 119:77-81, Elsevier Science (1997)	
	NPL28	Sandbulte, J., et al., "Evaluation of <i>Chlamydia psittaci</i> subfraction and subunit preparations for their protective capacities," <i>Vet. Microbiol.</i> 48:269-282, Elsevier Scientific Pub. Co (1996)	
	NPL29	Takahashi, I., et al., "Epitope Maps of the <i>Escherichia coli</i> Heat-Labile Toxin B Subunit for Development of a Synthetic Oral Vaccine," <i>Infect. Immun.</i> 64:1290-1298, American Society for Microbiology (1996)	
	NPL30	Wood, A.C., et al., "Identification of antigenic sites on staphylococcal enterotoxin B and toxoid," <i>FEMS Immunol. Med. Microbiol.</i> 17:1-10, Elsevier Science (1997)	
	NPL31	Yanagisawa, S., et al., "Mapping of V _β 11 ⁺ helper T cell epitopes on mycobacterial antigen in mouse primed with <i>Myobacterium tuberculosis</i> ," <i>Int. Immunol.</i> 9:227-237, Oxford University Press (1997)	

Examiner Signature

James Jackson

Date Considered

11/17

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

11/21/04

Substitute for form 1449B/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				<i>Application Number</i>	10/701,844
				<i>Filing Date</i>	November 4, 2003
				<i>First Named Inventor</i>	W. James JACKSON
				<i>Art Unit</i>	1645
				<i>Examiner Name</i>	Baskar, Padmavathi
Sheet	4	of	4	<i>Attorney Docket Number</i>	2479.0040002/EJK/C-K

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published				T ²
	NPL32	Zhao, Q., <i>et al.</i> , "Recall of Original Serologic Response after Challenge with Homologues and Heterologous <i>Chlamydia trachomatis</i> Serovars," <i>J. Infect. Dis.</i> 173:609 -618, The University of Chicago Stet (1996)				
	NPL33	Zhong, G., <i>et al.</i> , "Antibody Recognition of a Neutralization Epitope on the Major Outer Membrane Protein of <i>Chlamydia trachomatis</i> ," <i>Infect. Immun.</i> 62:1576-1583, American Society for Microbiology (1994)				
	NPL34	Zhu, Y., <i>et al.</i> , "Identification of a <i>Coccidioides immitis</i> Antigen 2 Domain That Expresses B-Cell-Reactive Epitopes," <i>Infect. Immun.</i> 65:3376-3380, American Society for Microbiology (1997)				
	NPL35	Copy of co-pending U.S. Application No. 08/942,596, inventors Jackson, W.J., <i>et al.</i> , filed October 2, 1997 (NOT PUBLISHED)				

585990v1

Examiner Signature		Date Considered	
--------------------	---	-----------------	---

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

8/1/07

Substitute for form 1449/PTO				<i>Complete if Known</i>		
SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/701,844	
Sheet	1	of	3	Filing Date	November 4, 2003	
				First Named Inventor	JACKSON, W. James	
				Art Unit	1645	
				Examiner Name	BASKAR, Padmavathi	
				Attorney Docket Number		2479.0040002/EJH/C-K

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published				T ²
/PB/	NPL36	BATTEIGER, B.E., <i>et al.</i> , "Partial protection against genital reinfection by immunization of guinea-pigs with isolated outer-membrane proteins of the chlamydial agent of guinea-pig inclusion conjunctivitis," <i>J. Gen. Microbiol.</i> 139:2965-2972, SGM (1993)				
/PB/	NPL37	BORK, P., "Go hunting in sequence databases but watch out for the traps," <i>Trends Genet.</i> 12:425-427, Elsevier Science Ltd. (October 1996)				
/PB/	NPL38	BORK, P., "Powers and Pitfalls in Sequence Analysis: The 70% Hurdle," <i>Genome Res.</i> 10:398-400, Cold Spring Harbor Laboratory Press (April 2000)				
/PB/	NPL39	BRENNER, S.E., "Errors in genome annotation," <i>Trends Genet.</i> 15:132-133, Elsevier Science Ltd. (April 1999)				
/PB/	NPL40	BUSH, R.M., and EVERETT, K.D.E., "Molecular evolution of the <i>Chlamydiaceae</i> ," <i>Int. J. Syst. Evol. Microbiol.</i> 51:203-220, IUMS (January 2001)				
/PB/	NPL41	CLYNE, J.M., <i>et al.</i> , "A Rapid Chemiluminescent DNA Hybridization Assay for the Detection of <i>Chlamydia Trachomatis</i> ," <i>J. Biolumin. Chemilumin.</i> 4:357-366, John Wiley & Sons, Ltd. (1989)				
/PB/	NPL42	DOERKS, T., <i>et al.</i> , "Protein annotation: detective work for function prediction," <i>Trends Genet.</i> 14:248-250, Elsevier Science Ltd. (June 1998)				
/PB/	NPL43	KRIEG, A.M., "Therapeutic potential of Toll-like receptor 9 activation," <i>Nature Rev. Drug Discov.</i> 5:471-484, Nature Publishing Group (June 2006)				
/PB/	NPL44	MYGIND, P.H., <i>et al.</i> , "Membrane proteins PmpG and PmpH are major constituents of <i>Chlamydia trachomatis</i> L2 outer membrane complex," <i>FEMS Microbiol. Lett.</i> 186:163-169, Elsevier Science B.V. (May 2000)				
/PB/	NPL45	NCBI Entrez, GenBank Report, Accession No. ABB22785, Halse, T.A., <i>et al.</i> (First entered October 2005 and last revised August 2006)				

Examiner Signature	/Padmavathi Baskar/	Date Considered	08/02/2007
--------------------	---------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO				<i>Complete if Known</i>	
SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/701,844
Sheet	2	of	3	Filing Date	November 4, 2003
				First Named Inventor	JACKSON, W. James
				Art Unit	1645
				Examiner Name	BASKAR, Padmavathi
				Attorney Docket Number	2479.0040002/EJH/C-K

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published			
/PB/	NPL46	NGO, J.T., <i>et al.</i> , "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox—Future Work," in <i>The Protein Folding Problem and Tertiary Structure Prediction</i> , Merz, Jr., K.M., and Le Grand, S.M., eds., Birkhäuser, Boston, MA, pp. 492-495 (1994)			
/PB/	NPL47	PEIPERT, J.F., "Genital Chlamydial Infections," <i>N. Engl. J. Med.</i> 349:2424-2430, Massachusetts Medical Society (December 2003)			
/PB/	NPL48	SHAW, A.C., <i>et al.</i> , "Comparative proteome analysis of <i>Chlamydia trachomatis</i> serovar A, D, and L2," <i>Proteomics</i> 2:164-186, Wiley-VCH Verlag GmbH (February 2002)			
/PB/	NPL49	SKOLNICK, J., and FETROW, J.S., "From genes to protein structure and function: novel applications of computational approaches in the genomic era," <i>Trends Biotechnol.</i> 18:34-39, Elsevier Science Ltd. (January 2000)			
/PB/	NPL50	SMITH, J.A., "Analysis of Proteins," in <i>Short Protocols in Molecular Biology</i> 3 rd ed., Ausubel, F.M., <i>et al.</i> , eds. John Wiley & Sons, Inc., United States (1997)			
/PB/	NPL51	SMITH, T.F., and ZHANG, X., "The challenges of genome sequence annotation or "The devil is in the details," <i>Nature Biotechnol.</i> 15:1222-1223, Nature America, Inc. (November 1997)			
/PB/	NPL52	STEPHENS, R.S., <i>et al.</i> , "Genome Sequence of an Obligate Intracellular Pathogen of Humans: <i>Chlamydia trachomatis</i> ," <i>Science</i> 282:754-759, American Association for the Advancement of Science (October 1998)			
/PB/	NPL53	SU, H., <i>et al.</i> , "Protective efficacy of a parenterally administered MOMP-derived synthetic oligopeptide vaccine in a murine model of <i>Chlamydia trachomatis</i> genital tract infection: serum neutralizing IgG antibodies do not protect against chlamydial genital tract infection," <i>Vaccine</i> 13:1023-1032, Elsevier Science Ltd. (1995)			
/PB/	NPL54	TANZER, R.J., and HATCH, T.P., "Characterization of Outer Membrane Proteins in <i>Chlamydia trachomatis</i> LGV Serovar L2," <i>J. Bacteriol.</i> 183:2686-2690, American Society of Microbiology (April 2001)			
/PB/	NPL55	TUFFREY, M., <i>et al.</i> , "Heterotypic protection of mice against chlamydial salpingitis and colonization of the lower genital tract with a human serovar F isolate of <i>Chlamydia trachomatis</i> by prior immunization with recombinant serovar L1 major outer-membrane protein," <i>J. Gen. Microbiol.</i> 138:1707-1715, SGM (1992)			

Examiner Signature	/Padmavathi Baskar/	Date Considered	08/02/2007
--------------------	---------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO				<i>Complete if Known</i>	
SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/701,844
				Filing Date	November 4, 2003
				First Named Inventor	JACKSON, W. James
				Art Unit	1645
				Examiner Name	BASKAR, Padmavathi
Sheet		3	of	3	Attorney Docket Number
2479.0040002/EJH/C-K					

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published				T ²
/PB/	NPL56	Webster's New World Dictionary, Third College Edition, Webster's New World Dictionaries, New York, NY, pp. 675, 1472 (1988)				
/PB/	NPL57	WELLS, J.A., "Additivity of Mutational Effects in Proteins," <i>Biochemistry</i> 29:8509-8517, American Chemical Society (1990)				

704597_1

Examiner Signature	/Padmavathi Baskar/	Date Considered	08/02/2007
--------------------	---------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete. Including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**SECOND SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Sheet 1 of 1

Substitute for form 1449/PTO				<i>Complete if Known</i>	
SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/701,844
				Filing Date	November 4, 2003
				First Named Inventor	JACKSON, W. James
				Art Unit	1645
				Examiner Name	BASKAR, Padmavathi
Sheet	1	of	1	Attorney Docket Number	2479.0040002/EJH/C-K

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

704574_1

Examiner Signature		Date Considered	8/1/05
-----------------------	---	--------------------	--------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.